All News

RheumNow Podcast square

Bah Humbug Vitamin D (12.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Seo RNL

Best of 2024: Vasculitis Pearls

Richard Conway, MBBChBAO, PhD

Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines. They really dropped a selection of pearls on us and I wanted to share a few of these with you.

Read Article
arttemp.jpg

Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes

Jack Cush, MD

A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. 

Read Article
question mark

ICYMI: Are Emulation Trials a Fantasy?

Janet Pope, MD, MPH, FRCPC

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
RheumNow Podcast square

54K Peptic Ulcers Annually (12.13.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
PMR,flag

ICYMI: Say Goodbye to Methotrexate in PMR?

Patricia Harkins, MD

For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.

Read Article
GCA temporal artery

Drug-Free Remission in Giant Cell Arteritis is Uncommon

Jack Cush, MD

A Spanish retrospective registry study of patients with giant cell arteritis (GCA) found that 3-4 years after diagnosis, only 21% of patients with GCA successfully reached the sustained drug-free remission (SDFR).

Read Article
GCA,woman

ICYMI: SELECT-GCA suggests JAKis may be the new kid on the block

Mrinalini Dey, MD

Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.

Read Article
Roundup cover

ACR24: Rheumatology Roundup

Jack Cush, MD

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Read Article
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/yHo5BNlbiL https://t.co/R2je32YYGy

Links:

Dr. John Cush RheumNow ( View Tweet)
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. https://t.co/nwCU3qW4PT https://t.co/uhvFDrW5Zz

Links:

Dr. John Cush RheumNow ( View Tweet)
Steroids do NOT hamper muscle Bx dx of ANCA vasculitis. Tokyo study of 126 pts w/ suspected vasculitis had Quad muscle Bx; 71 (+) w/ Dx of AAV. Bx yield in 56 and 15 pts w/ off or on steroids, respectively, was similar (59% vs 53%). https://t.co/Xpt01Wksd3 https://t.co/NSBclcEgwq

Links:

Dr. John Cush RheumNow ( View Tweet)
Avacopan, a C5aR antagonist, for Rx of ANCA-Assoc GPA & MPA. Main warning for liver AE. In RCTs, abnl LFTs seen in 11.6-13.3% and 4.2% D/C drug for liver probs. Recent Japanese report of 22 AAV pts with AVACO Liver injury seen in 9 pts - Severe, incr total bilirubin in 4, 1 pt… https://t.co/LyuIQhwOoQ https://t.co/TAmQ9vph4V
Dr. John Cush RheumNow ( View Tweet)
Review of IgA Vasculitis (Henoch–Schönlein Purpura) - the freq of glomerulonephritis is higher in adults than children and tends to present more severely. Rx w/ 1st line steroids, Other agents: Colchicine, dapsone, MTX (Minor dz), CsA, tacrolimus, MMF (steroid sparing)… https://t.co/tB5fll3RfN https://t.co/knc7KesyRj
Dr. John Cush RheumNow ( View Tweet)
Full Read Review of the Pulmonary Manifestations in Antisynthetase Syndrome (good reference!) https://t.co/gBLYRmHKE4 https://t.co/pUWmQCHk0N

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR24: What I learned in Sjogren's, Takayasu's and CAR-T Dr. Janet Pope reviews abstract 2527 and abstract 1696. https://t.co/rrrGnOhfIV https://t.co/Ht1UTtYOLI

Links:

Dr. John Cush RheumNow ( View Tweet)
SELECTing the right patients: upadacitinib in GCA Dr. Brian Jaros reports on abstract 1695, presented at #ACR24. https://t.co/x8lLTviOKk https://t.co/yXwwrdgIyu

Links:

Dr. John Cush RheumNow ( View Tweet)
🌟IgG4RD: Lessons from the first 20 years🌟by Prof John Stone ⭐️Lesson 1- IgG4RD is a variable vessel vasculitis ✨Can cause small vessel vasculitis of the skin ✨One of few vasculitis causing coronary arteritis in adults ⭐️Lesson 2- IgG4RD is more common and severe in males… https://t.co/PvFXyOl5bp https://t.co/hAMelBoZvB

Links:

Darpan Thakare darpan06T ( View Tweet)
A new score to quantify GCA inflammation? The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. #ACR24… https://t.co/b5H7KOtZPC https://t.co/AvrwHcXI7r
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in GCA? We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×